Faith D Ihekweazu1, Tatiana Fofanova2, Ryan Palacios3, Avanthi Ajjarapu3, Lina Karam3, Adam M Vogel4, J R Rodriguez4, Richard Kellermayer5. 1. Department of Pediatric Gastroenterology, Baylor College of Medicine, Texas Children's Hospital, 6701 Fannin St, MW1010, Houston, TX, 77030. Electronic address: faith.ihekweazu@bcm.edu. 2. Alkek Center for Metagenomics and Microbiome Research, Baylor College of Medicine, One Baylor Plaza, MS BCM385, Houston, TX 77030; Program in Translational Biology and Molecular Medicine, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030. 3. Department of Pediatric Gastroenterology, Baylor College of Medicine, Texas Children's Hospital, 6701 Fannin St, MW1010, Houston, TX, 77030. 4. Department of Pediatric Surgery, Baylor College of Medicine, Texas Children's Hospital, 6701 Fannin St, Houston, TX 77030. 5. Department of Pediatric Gastroenterology, Baylor College of Medicine, Texas Children's Hospital, 6701 Fannin St, MW1010, Houston, TX, 77030; USDA/ARS Children's Nutrition Research Center, 1100 Bates Ave, Houston, TX, 77030.
Abstract
BACKGROUND/ PURPOSE: Clinical outcomes in pediatric ulcerative colitis (UC) in the era of biologic agents are poorly defined. We aimed to describe risk factors for colectomy in pediatric UC in the era of infliximab therapy. METHODS: We reviewed 217 pediatric patients at Texas Children's Hospital with newly diagnosed UC between 2003 and 2015; 117 had a minimum of 5 years of follow-up. Extent of disease at diagnosis, medication exposure, the presence of extraintestinal manifestations (EIMs), and need for surgery were noted. RESULTS: Average length of follow up was 5.02 ± 2.27 years. Forty-two percent presented with pancolitis. Infliximab was used in 39%, immunomodulators in 65%, and steroids in 89% of patients. EIMs occurred in 24.9% of patients. The cumulative rate of colectomy was 12.9% at 5 years. Children presenting as E2 (Paris Classification) and children prescribed oral steroid monotherapy at diagnosis progressed to surgery faster than any other group. Of the children who received infliximab, females and children less than 5 years old were less likely to respond to therapy. CONCLUSIONS: The natural course of pediatric UC remains aggressive despite the addition of infliximab to the standard of care and suggests a need for early aggressive clinical intervention. LEVEL-OF-EVIDENCE RATING: Level IV.
BACKGROUND/ PURPOSE: Clinical outcomes in pediatric ulcerative colitis (UC) in the era of biologic agents are poorly defined. We aimed to describe risk factors for colectomy in pediatric UC in the era of infliximab therapy. METHODS: We reviewed 217 pediatric patients at Texas Children's Hospital with newly diagnosed UC between 2003 and 2015; 117 had a minimum of 5 years of follow-up. Extent of disease at diagnosis, medication exposure, the presence of extraintestinal manifestations (EIMs), and need for surgery were noted. RESULTS: Average length of follow up was 5.02 ± 2.27 years. Forty-two percent presented with pancolitis. Infliximab was used in 39%, immunomodulators in 65%, and steroids in 89% of patients. EIMs occurred in 24.9% of patients. The cumulative rate of colectomy was 12.9% at 5 years. Children presenting as E2 (Paris Classification) and children prescribed oral steroid monotherapy at diagnosis progressed to surgery faster than any other group. Of the children who received infliximab, females and children less than 5 years old were less likely to respond to therapy. CONCLUSIONS: The natural course of pediatric UC remains aggressive despite the addition of infliximab to the standard of care and suggests a need for early aggressive clinical intervention. LEVEL-OF-EVIDENCE RATING: Level IV.
Authors: Lorraine I Kelley-Quon; Howard C Jen; David A Ziring; Neera Gupta; Barbara S Kirschner; George D Ferry; Stanley A Cohen; Harland S Winter; Melvin B Heyman; Benjamin D Gold; Stephen B Shew Journal: J Pediatr Gastroenterol Nutr Date: 2012-11 Impact factor: 2.839
Authors: Melvin B Heyman; Barbara S Kirschner; Benjamin D Gold; George Ferry; Robert Baldassano; Stanley A Cohen; Harland S Winter; Patricia Fain; Chris King; Terry Smith; Hashem B El-Serag Journal: J Pediatr Date: 2005-01 Impact factor: 4.406
Authors: Johan Van Limbergen; Richard K Russell; Hazel E Drummond; Marian C Aldhous; Nicola K Round; Elaine R Nimmo; Linda Smith; Peter M Gillett; Paraic McGrogan; Lawrence T Weaver; W Michael Bisset; Gamal Mahdi; Ian D Arnott; Jack Satsangi; David C Wilson Journal: Gastroenterology Date: 2008-07-03 Impact factor: 22.682
Authors: Arie Levine; Anne Griffiths; James Markowitz; David C Wilson; Dan Turner; Richard K Russell; John Fell; Frank M Ruemmele; Thomas Walters; Mary Sherlock; Marla Dubinsky; Jeffrey S Hyams Journal: Inflamm Bowel Dis Date: 2010-11-08 Impact factor: 5.325
Authors: Ilyssa O Gordon; Suha Abushamma; Jacob A Kurowski; Stefan D Holubar; Lei Kou; Ruishen Lyu; Florian Rieder Journal: J Crohns Colitis Date: 2022-06-24 Impact factor: 10.020